Archana Singh-Manoux1, Martin J Shipley2, Joshua A Bell2, Marianne Canonico2, Alexis Elbaz2, Mika Kivimäki2. 1. INSERM U1018 Centre de recherche en Epidémiologie et Santé des Populations (Singh-Manoux, Canonico, Elbaz), Hôpital universitaire Paul-Brousse, Villejuif, France; Department of Epidemiology and Public Health (Shipley, Bell, Kivimäki), University College London, London, UK Archana.Singh-Manoux@inserm.fr. 2. INSERM U1018 Centre de recherche en Epidémiologie et Santé des Populations (Singh-Manoux, Canonico, Elbaz), Hôpital universitaire Paul-Brousse, Villejuif, France; Department of Epidemiology and Public Health (Shipley, Bell, Kivimäki), University College London, London, UK.
Abstract
BACKGROUND: The inflammatory biomarker α1-acid glycoprotein (AGP) was found to have the strongest association with 5-year mortality in a recent study of 106 biomarkers. We examined whether AGP is a better biomarker of mortality risk than the more widely used inflammatory biomarkers interleukin-6 (IL-6) and C-reactive protein (CRP). METHODS: We analyzed data for 6545 men and women aged 45-69 (mean 55.7) years from the Whitehall II cohort study. We assayed AGP, IL-6 and CRP levels from fasting serum samples collected in 1997-1999. Mortality followup was until June 2015. Cox regression analysis was used to model associations of inflammatory biomarkers with all-cause, cardiovascular and cancer-related mortality. RESULTS: Over the mean follow-up of 16.7 years, 736 deaths occurred, of which 181 were from cardiovascular disease and 347 from cancer. In the model adjusted for all covariates (age, sex, socioeconomic status, body mass index, health behaviours and chronic disease), AGP did not predict mortality beyond the first 5 years of follow-up; over this period, IL-6 and CRP had stronger associations with mortality. When we considered all covariates and biomarkers simultaneously, AGP no longer predicted all-cause mortality over the entire follow-up period (adjusted hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.90-1.08). Only IL-6 predicted all-cause mortality (adjusted HR 1.22, 95% CI 1.12-1.33) and cancer-related mortality (adjusted HR 1.13, 95% CI 1.00-1.29) over the entire follow-up period, whereas CRP predicted only cardiovascular mortality (adjusted HR 1.30, 95% CI 1.06-1.61). INTERPRETATION: Our findings suggest that AGP is not a better marker of short-or long-term mortality risk than the more commonly used biomarkers IL-6 and CRP.
BACKGROUND: The inflammatory biomarker α1-acid glycoprotein (AGP) was found to have the strongest association with 5-year mortality in a recent study of 106 biomarkers. We examined whether AGP is a better biomarker of mortality risk than the more widely used inflammatory biomarkers interleukin-6 (IL-6) and C-reactive protein (CRP). METHODS: We analyzed data for 6545 men and women aged 45-69 (mean 55.7) years from the Whitehall II cohort study. We assayed AGP, IL-6 and CRP levels from fasting serum samples collected in 1997-1999. Mortality followup was until June 2015. Cox regression analysis was used to model associations of inflammatory biomarkers with all-cause, cardiovascular and cancer-related mortality. RESULTS: Over the mean follow-up of 16.7 years, 736 deaths occurred, of which 181 were from cardiovascular disease and 347 from cancer. In the model adjusted for all covariates (age, sex, socioeconomic status, body mass index, health behaviours and chronic disease), AGP did not predict mortality beyond the first 5 years of follow-up; over this period, IL-6 and CRP had stronger associations with mortality. When we considered all covariates and biomarkers simultaneously, AGP no longer predicted all-cause mortality over the entire follow-up period (adjusted hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.90-1.08). Only IL-6 predicted all-cause mortality (adjusted HR 1.22, 95% CI 1.12-1.33) and cancer-related mortality (adjusted HR 1.13, 95% CI 1.00-1.29) over the entire follow-up period, whereas CRP predicted only cardiovascular mortality (adjusted HR 1.30, 95% CI 1.06-1.61). INTERPRETATION: Our findings suggest that AGP is not a better marker of short-or long-term mortality risk than the more commonly used biomarkers IL-6 and CRP.
Authors: Rahul Rawat; Jean H Humphrey; Kuda Mutasa; Robert Ntozini; Rebecca J Stoltzfus Journal: AIDS Res Hum Retroviruses Date: 2010-10-26 Impact factor: 2.205
Authors: G David Batty; Martin Shipley; Adam Tabák; Archana Singh-Manoux; Eric Brunner; Annie Britton; Mika Kivimäki Journal: Epidemiology Date: 2014-11 Impact factor: 4.822
Authors: M G Marmot; G D Smith; S Stansfeld; C Patel; F North; J Head; I White; E Brunner; A Feeney Journal: Lancet Date: 1991-06-08 Impact factor: 79.321
Authors: Daniel I Swerdlow; Michael V Holmes; Karoline B Kuchenbaecker; Jorgen E L Engmann; Tina Shah; Reecha Sofat; Yiran Guo; Christina Chung; Anne Peasey; Roman Pfister; Simon P Mooijaart; Helen A Ireland; Maarten Leusink; Claudia Langenberg; Ka Wah Li; Jutta Palmen; Philip Howard; Jackie A Cooper; Fotios Drenos; John Hardy; Michael A Nalls; Yun Rose Li; Gordon Lowe; Marlene Stewart; Suzette J Bielinski; Julian Peto; Nicholas J Timpson; John Gallacher; Malcolm Dunlop; Richard Houlston; Ian Tomlinson; Ioanna Tzoulaki; Jian'an Luan; Jolanda M A Boer; Nita G Forouhi; N Charlotte Onland-Moret; Yvonne T van der Schouw; Renate B Schnabel; Jaroslav A Hubacek; Ruzena Kubinova; Migle Baceviciene; Abdonas Tamosiunas; Andrzej Pajak; Roman Topor-Madry; Sofia Malyutina; Damiano Baldassarre; Bengt Sennblad; Elena Tremoli; Ulf de Faire; Luigi Ferrucci; Stefania Bandenelli; Toshiko Tanaka; James F Meschia; Andrew Singleton; Gerjan Navis; Irene Mateo Leach; Stephan J L Bakker; Ron T Gansevoort; Ian Ford; Stephen E Epstein; Mary Susan Burnett; Joe M Devaney; J Wouter Jukema; Rudi G J Westendorp; Gert Jan de Borst; Yolanda van der Graaf; Pim A de Jong; Anke-Hilse Mailand-van der Zee; Olaf H Klungel; Anthonius de Boer; Pieter A Doevendans; Jeffrey W Stephens; Charles B Eaton; Jennifer G Robinson; JoAnn E Manson; F Gerry Fowkes; Timonthy M Frayling; Jackie F Price; Peter H Whincup; Richard W Morris; Debbie A Lawlor; George Davey Smith; Yoav Ben-Shlomo; Susan Redline; Leslie A Lange; Meena Kumari; Nick J Wareham; W M Monique Verschuren; Emelia J Benjamin; John C Whittaker; Anders Hamsten; Frank Dudbridge; J A Chris Delaney; Andrew Wong; Diana Kuh; Rebecca Hardy; Berta Almoguera Castillo; John J Connolly; Pim van der Harst; Eric J Brunner; Michael G Marmot; Christina L Wassel; Steve E Humphries; Philippa J Talmud; Mika Kivimaki; Folkert W Asselbergs; Mikhail Voevoda; Martin Bobak; Hynek Pikhart; James G Wilson; Hakon Hakonarson; Alex P Reiner; Brendan J Keating; Naveed Sattar; Aroon D Hingorani; Juan Pablo Casas Journal: Lancet Date: 2012-03-14 Impact factor: 79.321
Authors: Nadeem Sarwar; Adam S Butterworth; Daniel F Freitag; John Gregson; Peter Willeit; Donal N Gorman; Pei Gao; Danish Saleheen; Augusto Rendon; Christopher P Nelson; Peter S Braund; Alistair S Hall; Daniel I Chasman; Anne Tybjærg-Hansen; John C Chambers; Emelia J Benjamin; Paul W Franks; Robert Clarke; Arthur A M Wilde; Mieke D Trip; Maristella Steri; Jacqueline C M Witteman; Lu Qi; C Ellen van der Schoot; Ulf de Faire; Jeanette Erdmann; Heather M Stringham; Wolfgang Koenig; Daniel J Rader; David Melzer; David Reich; Bruce M Psaty; Marcus E Kleber; Demosthenes B Panagiotakos; Johann Willeit; Patrik Wennberg; Mark Woodward; Svetlana Adamovic; Eric B Rimm; Tom W Meade; Richard F Gillum; Jonathan A Shaffer; Albert Hofman; Altan Onat; Johan Sundström; Sylvia Wassertheil-Smoller; Dan Mellström; John Gallacher; Mary Cushman; Russell P Tracy; Jussi Kauhanen; Magnus Karlsson; Jukka T Salonen; Lars Wilhelmsen; Philippe Amouyel; Bernard Cantin; Lyle G Best; Yoav Ben-Shlomo; JoAnn E Manson; George Davey-Smith; Paul I W de Bakker; Christopher J O'Donnell; James F Wilson; Anthony G Wilson; Themistocles L Assimes; John-Olov Jansson; Claes Ohlsson; Åsa Tivesten; Östen Ljunggren; Muredach P Reilly; Anders Hamsten; Erik Ingelsson; Francois Cambien; Joseph Hung; G Neil Thomas; Michael Boehnke; Heribert Schunkert; Folkert W Asselbergs; John J P Kastelein; Vilmundur Gudnason; Veikko Salomaa; Tamara B Harris; Jaspal S Kooner; Kristine H Allin; Børge G Nordestgaard; Jemma C Hopewell; Alison H Goodall; Paul M Ridker; Hilma Hólm; Hugh Watkins; Willem H Ouwehand; Nilesh J Samani; Stephen Kaptoge; Emanuele Di Angelantonio; Olivier Harari; John Danesh Journal: Lancet Date: 2012-03-14 Impact factor: 79.321
Authors: K So-Armah; S K Gupta; S Kundu; J C Stewart; J L Goulet; A A Butt; J J Sico; V C Marconi; S Crystal; M C Rodriguez-Barradas; M Budoff; C L Gibert; C-Ch Chang; R Bedimo; M S Freiberg Journal: HIV Med Date: 2019-03-29 Impact factor: 3.180
Authors: Edna Maria Vissoci Reiche; Jair Roberto Gelinksi; Daniela Frizon Alfieri; Tamires Flauzino; Marcio Francisco Lehmann; Maria Caroline Martins de Araújo; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Elaine Regina Delicato de Almeida; Michael Maes Journal: Metab Brain Dis Date: 2019-03-14 Impact factor: 3.584
Authors: Antonio Bernabe-Ortiz; Rodrigo M Carrillo-Larco; Robert H Gilman; Liam Smeeth; William Checkley; J Jaime Miranda Journal: Ann Epidemiol Date: 2021-12-16 Impact factor: 3.797
Authors: Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky Journal: J Am Coll Cardiol Date: 2020-06-02 Impact factor: 24.094
Authors: Martin F Bourgonje; Arno R Bourgonje; Amaal E Abdulle; Lyanne M Kieneker; Sacha la Bastide-van Gemert; Ron T Gansevoort; Stephan J L Bakker; Douwe J Mulder; Andreas Pasch; Jumana Saleh; Sanne J Gordijn; Harry van Goor Journal: Front Cardiovasc Med Date: 2021-02-09
Authors: P A Stapleton; Q A Hathaway; C E Nichols; A B Abukabda; M V Pinti; D L Shepherd; C R McBride; J Yi; V C Castranova; J M Hollander; T R Nurkiewicz Journal: Part Fibre Toxicol Date: 2018-01-10 Impact factor: 9.400
Authors: Zhuoyun Li; Yasheen Gao; Doratha A Byrd; David C Gibbs; Anna E Prizment; DeAnn Lazovich; Roberd M Bostick Journal: J Nutr Date: 2021-04-08 Impact factor: 4.798
Authors: Renate S Olsen; Johnny Nijm; Roland E Andersson; Jan Dimberg; Dick Wågsäter Journal: World J Gastroenterol Date: 2017-09-14 Impact factor: 5.742